Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study

Authors: Pabst, Thomas, Papayannidis, Cristina, Demirkan, Fatih, Doronin, Vadim, Fogliatto, Laura M, Guttke, Christina, Gyan, Emmanuel, Hamad, Nada, Herrera, Pilar, Hultberg, Anna, Jacobs, Julie, Johnson, Amy J, Langlois, Angélique, Ma, Xuewen, Martinelli, Giovanni, Arnan, Montserrat, Müller, Rouven, Nottage, Kerri, Ofran, Yishai, Özcan, Muhit, Samoilova, Olga, Tolbert, Jaszianne A, Trudel, Géralyn C ^†, Xiu, Liang, Vey, Norbert, Wei, Andrew H ^*

Source: In The Lancet Haematology November 2023 10(11):e902-e912

“Lawful interception – A market access barrier in the European Union”?

Authors: Doronin, Vadim

Source: In Computer Law & Security Review: The International Journal of Technology Law and Practice November 2023 51

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Authors: de Botton, Stéphane ^∗, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Ommen, Hans, Semochkin, Sergey, Kim, Hee-Je, Larson, Richard A., Koprivnikar, Jaime, Frankfurt, Olga, Thol, Felicitas, Chromik, Jörg, Byrne, Jenny, Pigneux, Arnaud, Thomas, Xavier, Salamero, Olga, Vidriales, Maria Belen, Doronin, Vadim, Döhner, Hartmut, Fathi, Amir T., Laille, Eric, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, DiNardo, Courtney D.

Source: In Blood 12 January 2023 141(2):156-167

Efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice‐weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study

Authors: Delimpasi, Sosana, Mateos, Maria Victoria, Auner, Holger W., Gavriatopoulou, Maria, Dimopoulos, Meletios A., Quach, Hang, Pylypenko, Halyna, Hájek, Roman, Leleu, Xavier, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Benjamin, Reuben, Garg, Mamta Krishnan, Doronin, Vadim, Levy, Yair, Moreau, Philippe, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., Grosicki, Sebastian

Source: American journal of hematology. 97(3):E83-E86

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100139958882.0x000001&indx=1&recIds=ETOCvdc_100139958882.0x000001

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Authors: Schjesvold, Fredrik H, Dimopoulos, Meletios-Athanasios, Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Legiec, Wojciech, Pour, Luděk, Špička, Ivan, Masszi, Tamas, Doronin, Vadim, Minarik, Jiri, Salogub, Galina, Alekseeva, Yulia, Lazzaro, Antonio, Maisnar, Vladimir, Mikala, Gábor, Rosiñol, Laura, Liberati, Anna Marina, Symeonidis, Argiris, Moody, Victoria, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A, Hájek, Roman, Mateos, Maria-Victoria, Richardson, Paul G, Sonneveld, Pieter

Source: Lancet.Haematology. 9(2):e98-e110

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183249030.0x000001&indx=1&recIds=ETOCvdc_100183249030.0x000001

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML

Authors: Adès, Lionel ^*, Girshova, Larisa, Doronin, Vadim A., Díez-Campelo, María, Valcárcel, David, Kambhampati, Suman, Viniou, Nora-Athina, Woszczyk, Dariusz, De Paz Arias, Raquel, Symeonidis, Argiris, Anagnostopoulos, Achilles, Munhoz, Eduardo Ciliao, Platzbecker, Uwe, Santini, Valeria, Fram, Robert J., Yuan, Ying, Friedlander, Sharon, Faller, Douglas V., Sekeres, Mikkael A.

Source: In Blood Advances 13 September 2022 6(17):5132-5145

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Authors: Auner, Holger W., Gavriatopoulou, Maria, Delimpasi, Sosana, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Dimopoulos, Meletios A., Kriachok, Iryna, Pylypenko, Halyna, Leleu, Xavier, Doronin, Vadim, Usenko, Ganna, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan Kanti, Sinha, Dinesh Kumar, Venner, Christopher P., Garg, Mamta, Stevens, Don Ambrose, Quach, Hang, Jagannath, Sundar, Moreau, Phillipe, Levy, Moshe, Badros, Ashraf, Anderson, Larry D., Bahlis, Nizar J., Facon, Thierry, Mateos, Maria Victoria, Cavo, Michele, Chai, Yi, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., Richardson, Paul G., Grosicki, Sebastian

Source: American journal of hematology. 96(6):708-718

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100121327976.0x000001&indx=1&recIds=ETOCvdc_100121327976.0x000001

Daratumumab in transfusion‐dependent patients with low or intermediate‐1 risk myelodysplastic syndromes

Authors: Garcia‐Manero, Guillermo, Diez‐Campelo, Maria, Vellenga, Edo, Jacoby, Meagan A., Merchan, Brayan, Breems, Dimitri, Cortelezzi, Agostino, Doronin, Vadim, Gomez, Valle, Beckers, Marielle, Della Porta, Matteo Giovanni, Varsos, Helen, Xiu, Liang, DeAngelis, Nikki, Nnane, Ivo, Rose, Esther, Eygen, Koen

Source: American journal of hematology. 96(4):E111-E114

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100120767024.0x000001&indx=1&recIds=ETOCvdc_100120767024.0x000001

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Authors: Grosicki, Sebastian ^*, Simonova, Maryana, Spicka, Ivan, Pour, Ludek, Kriachok, Iryrna, Gavriatopoulou, Maria, Pylypenko, Halyna, Auner, Holger W, Leleu, Xavier, Doronin, Vadim, Usenko, Ganna, Bahlis, Nizar J, Hajek, Roman, Benjamin, Reuben, Dolai, Tuphan K, Sinha, Dinesh K, Venner, Christopher P, Garg, Mamta, Gironella, Mercedes, Jurczyszyn, Artur, Robak, Pawel, Galli, Monica, Wallington-Beddoe, Craig, Radinoff, Atanas, Salogub, Galina, Stevens, Don A, Basu, Supratik, Liberati, Anna M, Quach, Hang, Goranova-Marinova, Vesselina S, Bila, Jelena, Katodritou, Eirini, Oliynyk, Hanna, Korenkova, Sybiryna, Kumar, Jeevan, Jagannath, Sundar, Moreau, Phillipe, Levy, Moshe, White, Darrell, Gatt, Moshe E, Facon, Thierry, Mateos, Maria V, Cavo, Michele, Reece, Donna, Anderson, Larry D, Jr, Saint-Martin, Jean-Richard, Jeha, Jacqueline, Joshi, Anita A, Chai, Yi, Li, Lingling, Peddagali, Vishnuvardhan, Arazy, Melina, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G, Dimopoulos, Meletios A, Richardson, Paul G, Delimpasi, Sosana

Source: In The Lancet 14-20 November 2020 396(10262):1563-1573

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Authors: Attal, Michel, Richardson, Paul G., Rajkumar, Vincent, San-Miguel, Jesus, Beksac, Meral, Spicka, Ivan, Leleu, Xavier, Schjesvold, Fredrik, Moreau, Philippe, Dimopoulos, Meletios A., Huang, Jeffrey Shang-Yi, Minarik, Jiri, Cavo, Michele, Prince, H. Miles, Macé, Sandrine, Corzo, Kathryn P., Campana, Frank, Le-Guennec, Solenn, Dubin, Franck, Anderson, Kenneth C., Harrison, Simon, Janowski, Wojt, Kerridge, Ian, Spencer, Andrew, Delforge, Michel, Fostier, Karel, Vlummens, Philip, Wu, Ka Lung, Leblanc, Richard, Pavic, Michel, Sebag, Michael, Hajek, Roman, Maisnar, Vladimir, Pour, Ludek, Gregersen, Henrik, Benbouker, Lotfi, Caillot, Denis, Escoffre-Barbe, Martine, Facon, Thierry, Frenzel, Laurent, Hulin, Cyrille, Karlin, Lionel, Kolb, Brigitte, Pegourie, Brigitte, Perrot, Aurore, Tiab, Mourad, Vincent, Laure, Niederwieser, Dietger, Anagnostopoulos, Achilles, Delimpasi, Sosana, Kyrtsonis, Marie-Christine, Symeonidis, Anargyros, Illes, Arpad, Mikala, Gabor, Nagy, Zsolt, Bringen, Sara, Corradini, Paolo, Fabio, Ciceri, Lemoli, Roberto, Liberati, Anna, Nozzoli, Chiara, Zambello, Renato, Iida, Shinsuke, Ikeda, Takashi, Iyama, Satoshi, Matsumoto, Morio, Shimazaki, Chihiro, Sunami, Kazutaka, Suzuki, Kenshi, Uchiyama, Michihiro, Koh, Youngil, Kim, Kihyun, Lee, Jae Hoon, Min, Chang-Ki, Blacklock, Hillary, Goodman, Hugh, Neylon, Annette, Simpson, David, Grosicki, Sebastian, Jurczyszyn, Artur, Walter-Croneck, Adam, Warzocha, Krzysztof, Araujo, Luis, Moreira, Claudia, Doronin, Vadim, Mendeleeva, Larisa, Vorobyev, Vladimir, Vranovsky, Andrej, Alegre, Adrian, Gironella, Mercedes, Gonzalez Perez, Marta Sonia, Montes, Carmen, Ocio, Enrique, Rodriguez, Paula, Hardling, Mats, Lauri, Birgitta, Wang, Ming-Chung, Yeh, Su-Peng, Arat, Mutlu, Demirkan, Fatih, Gulbas, Zafer, Besisik, Sevgi Kalayoglu, Karadogan, Ihsan, Tuglular, Tulin, Unal, Ali, Vural, Filiz, Sive, Jonathan, Streetly, Matthew, Yong, Kwee, Tache, Jason, Richardson, Paul G ^{*, **}, Rajkumar, S Vincent, Dimopoulos, Meletios A, Prince, H Miles, Corzo, Kathryn P, Anderson, Kenneth C

Source: In The Lancet 7-13 December 2019 394(10214):2096-2107

Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone

Authors: Sanchez, Larysa ^*, Leleu, Xavier, Beaumont, Jennifer ^*, Yu, Hailin ^*, Hudgens, Stacie ^*, Auner, Holger W, Quach, Hang, Delimpasi, Sosana ^*, Spicka, Ivan ^*, Pour, Luděk ^*, Dimopoulos, Meletios A, Pylypenko, Halyna ^*, Doronin, Vadim A ^*, Usenko, Ganna ^*, Hajek, Roman, Benjamin, Reuben, Venner, Christopher P., Garg, Mamta ^*, Stevens, Don A., Jagannath, Sundar ^*, Moreau, Philippe ^*, Levy, Moshe ^*, Bahlis, Nizar J., Facon, Thierry ^*, Chai, Yi ^*, Ma, Xiwen ^*, Tang, Shijie ^*, Leong, Hoyee ^*, Shah, Jatin J. ^*, Shacham, Sharon ^*, Kauffman, Michael G, Richardson, Paul G., Grosicki, Sebastian

Source: In Blood 5 November 2020 136 Supplement 1:39-41

Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study

Authors: Mateos, Maria ^*, Jagannath, Sundar, Delimpasi, Sosana ^*, Simonova, Maryana ^*, Spicka, Ivan ^*, Pour, Ludek ^*, Kryachok, Irina ^*, Gavriatopoulou, Maria ^*, Dimopoulos, Meletios A, Pylypenko, Halyna ^*, Auner, Holger W, Leleu, Xavier, Doronin, Vadim A ^*, Usenko, Ganna ^*, Benjamin, Reuben, Dolai, Tuphan Kanti ^*, Sinha, Dinesh Kumar ^*, Venner, Christopher P., Garg, Mamta ^*, Stevens, Don A., Quach, Hang, Moreau, Philippe ^*, Levy, Moshe Y., Badros, Ashraf Z., Anderson, Larry D., Jr., Bahlis, Nizar J., Facon, Thierry ^*, Cavo, Michele ^*, Chai, Yi ^*, Arazy, Melina ^*, Shah, Jatin, Shacham, Sharon ^*, Kauffman, Michael G, Richardson, Paul G., Grosicki, Sebastian

Source: In Blood 5 November 2020 136 Supplement 1:50-52

Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study

Authors: Mateos, Maria ^*, Gavriatopoulou, Maria ^*, Facon, Thierry ^*, Auner, Holger W, Leleu, Xavier, Hajek, Roman, Dimopoulos, Meletios A, Delimpasi, Sosana ^*, Simonova, Maryana ^*, Spicka, Ivan ^*, Pour, Ludek ^*, Kryachok, Irina ^*, Pylypenko, Halyna ^*, Doronin, Vadim A ^*, Usenko, Ganna ^*, Benjamin, Reuben ^*, Dolai, Tuphan Kanti ^*, Sinha, Dinesh Kumar ^*, Venner, Christopher P., Garg, Mamta ^*, Stevens, Don A., Quach, Hang, Jagannath, Sundar ^*, Moreau, Philippe ^*, Levy, Moshe ^*, Badros, Ashraf Z., Anderson, Larry D., Jr., Bahlis, Nizar J., Cavo, Michele ^*, Chai, Yi ^*, Arazy, Melina ^*, Shah, Jatin, Shacham, Sharon ^*, Kauffman, Michael G, Richardson, Paul G., Grosicki, Sebastian

Source: In Blood 5 November 2020 136 Supplement 1:48-50

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Authors: Schjesvold, Fredrik, Dimopoulos, Meletios A., Delimpasi, Sosana, Robak, Pawel, Coriu, Daniel, Legiec, Wojciech Maciej, Pour, Ludek, Spicka, Ivan, Masszi, Tamas, Doronin, Vadim Anatolievich, Minarik, Jiri, Salogub, Galina, Alexeeva, Yulia, Lazzaro, Antonio, Maisnar, Vladimir, Mikala, Gabor, Norin, Stefan, Thuresson, Marcus, Bergan, Anna, Obermüller, Jakob, Hajek, Roman, Mateos, Maria-Victoria, Richardson, Paul G., Sonneveld, Pieter

Source: In Blood 2 November 2023 142 Supplement 1:2018-2018

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2relapsed/refractory AML: a randomized phase 3 trial

Authors: de Botton, Stéphane, Montesinos, Pau, Schuh, Andre C., Papayannidis, Cristina, Vyas, Paresh, Wei, Andrew H., Ommen, Hans, Semochkin, Sergey, Kim, Hee-Je, Larson, Richard A., Koprivnikar, Jaime, Frankfurt, Olga, Thol, Felicitas, Chromik, Jörg, Byrne, Jenny, Pigneux, Arnaud, Thomas, Xavier, Salamero, Olga, Vidriales, Maria Belen, Doronin, Vadim, Döhner, Hartmut, Fathi, Amir T., Laille, Eric, Yu, Xin, Hasan, Maroof, Martin-Regueira, Patricia, DiNardo, Courtney D.

Source: Blood; January 2023, Vol. 141 Issue: 2 p156-167, 12p

Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.

Authors: Dimopoulos, Meletios A., Schjesvold, Fredrik, Doronin, Vadim, Vinogradova, Olga, Quach, Hang, Leleu, Xavier, Yolanda, Gonzalez montes, Ramasamy, Karthik, Pompa, Alessandra, Levin, Mark-David, Lee, Cindy, Mellqvist, Ulf-Henrik, Fenk, Roland, Sati, Hamdi, Vorog, Alexander, Labotka, Richard J., Du, Jichang, Darif, Mohamed, Kumar, Shaji

Source: Journal of clinical oncology. 39(15 suppl):8020-8020

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173216933.0x000001&indx=1&recIds=ETOCvdc_100173216933.0x000001

OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Authors: Schjesvold, Fredrik, Dimopoulos, Meletios-Athanasios, Delimpasi, Sosana, Robak, Pawef, Coriu, Daniel, Legiec, Wojciech, Pour, Luděk, Špička, Ivan, Masszi, Tamás, Doronin, Vadim, Minarik, Jiri, Salogub, Galina, Alexeeva, Yulia, Lazzaro, Antonio, Maisnar, Vladimir, Mikala, Gábor, Moody, Victoria, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Hájek, Roman, Mateos, María-Victoria, Richardson, Paul G., Sonneveld, Pieter

Source: Clinical lymphoma, myeloma & leukemia. 21(S2):S32-S32

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100164504835.0x000001&indx=1&recIds=ETOCvdc_100164504835.0x000001

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma: Phase 2 study.

Authors: Boissel, Nicolas, Chevallier, Patrice, Doronin, Vadim, Griskevicius, Laimonas, Maschan, Alexey, McCloskey, James, Rambaldi, Alessandro, Rossi, Giuseppe, Sokolov, Andrey, Wartiovaara‐Kautto, Ulla, Oprea, Corina, Abbadessa, Giovanni, Gosselin, Alice, Macé, Sandrine, Thomas, Xavier

Source: Cancer Medicine; Mar2022, Vol. 11 Issue 5, p1292-1298, 7p

Subject Terms: LYMPHOBLASTIC leukemia, ACUTE diseases, OLDER patients, LYMPHOMAS, T-cell lymphoma, ADVERSE health care events

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.

Authors: Dimopoulos, Meletios A., Schjesvold, Fredrik, Doronin, Vadim, Vinogradova, Olga, Quach, Hang, Leleu, Xavier, Montes, Yolanda Gonzalez, Ramasamy, Karthik, Pompa, Alessandra, Levin, Mark-David, Lee, Cindy, Mellqvist, Ulf Henrik, Fenk, Roland, Demarquette, Hélène, Sati, Hamdi, Vorog, Alexander, Labotka, Richard, Du, Jichang, Darif, Mohamed, Kumar, Shaji

Source: Blood Cancer Journal; Jan2022, Vol. 12 Issue 1, p1-10, 10p

Subject Terms: BORTEZOMIB, MULTIPLE myeloma, PROGRESSION-free survival, LENALIDOMIDE, QUALITY of life

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

Authors: Mateos, Maria V., Gavriatopoulou, Maria, Facon, Thierry, Auner, Holger W., Leleu, Xavier, Hájek, Roman, Dimopoulos, Meletios A., Delimpasi, Sosana, Simonova, Maryana, Špička, Ivan, Pour, Ludĕk, Kriachok, Iryna, Pylypenko, Halyna, Doronin, Vadim, Usenko, Ganna, Benjamin, Reuben, Dolai, Tuphan K., Sinha, Dinesh K., Venner, Christopher P., Garg, Mamta

Source: Journal of Hematology & Oncology; 4/13/2021, Vol. 14 Issue 1, p1-5, 5p

Subject Terms: MULTIPLE myeloma, BORTEZOMIB, DRUG efficacy, DEXAMETHASONE, DRUG therapy